×
About 19,788 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,941 results

Evaluating surface EMG control of motorized wheelchairs for amyotrophic lateral scleros...
https://doi.org/10.1186/s12984-022-01066-8
Journal of Neuroengineering and Rehabilitation; Manero AC, McLinden SL et. al.

Aug 15th, 2022 - This study evaluated a novel control method for patients unable to independently control powered wheelchairs. Patients with amyotrophic lateral sclerosis often require a wheelchair but struggle with sufficient hand dexterity required for joystick ...

Respiratory neuroplasticity: Mechanisms and translational implications of phrenic motor...
https://doi.org/10.1016/B978-0-323-91534-2.00016-3
Handbook of Clinical Neurology; Mitchell GS, Baker TL

Aug 15th, 2022 - Widespread appreciation that neuroplasticity is an essential feature of the neural system controlling breathing has emerged only in recent years. In this chapter, we focus on respiratory motor plasticity, with emphasis on the phrenic motor system....

Characterisation of retrotransposon insertion polymorphisms in whole genome sequencing ...
https://doi.org/10.1016/j.gene.2022.146799
Gene Savage AL, Iacoangeli A et. al.

Aug 14th, 2022 - The genetics of an individual is a crucial factor in understanding the risk of developing the neurodegenerative disease amyotrophic lateral sclerosis (ALS). There is still a large proportion of the heritability of ALS, particularly in sporadic cas...

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in ...
https://doi.org/10.1016/j.ebiom.2022.104202
EBioMedicine Chaytow H, Carroll E et. al.

Aug 14th, 2022 - Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with heterogeneous aetiology and a complex genetic background. Effective therapies are therefore likely to act on convergent pathways such as dysregulated energy metabolism,...

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05163886

Aug 12th, 2022 - This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, biomarker-driven clinical trial evaluating the safety, tolerability, and biological effect of LAM-002A in approximately 12 adults with C9ORF72-associated ALS (C9ALS). I...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  539 results

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05163886

Aug 12th, 2022 - This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, biomarker-driven clinical trial evaluating the safety, tolerability, and biological effect of LAM-002A in approximately 12 adults with C9ORF72-associated ALS (C9ALS). I...

Colchicine for Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT03693781

Aug 11th, 2022 - Recent evidence supports the disruption of the ubiquitin-proteasome-system and autophagy as central events in ALS. ALS is characterized by the presence of misfolded proteins prone to oligomerize into aggregates, which exert a toxic effect by affec...

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
https://clinicaltrials.gov/ct2/show/NCT05218668

Aug 11th, 2022 - The study population will consist of subjects with a diagnosis of probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria; with ALS symptom onset within 48 months; and with percent predic...

Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT04840823

Aug 11th, 2022 - Participants will be randomized to one of three doses of enoxacin (200, 400, or 600mg twice daily) for 30 days. On day 1, 7, 14, 21, and 30 of treatment and at a follow-up visit 14 days after the last dose, participants will be assessed for safety...

Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT02588807

Aug 9th, 2022 - This is an open label pilot study, where patients (n=10) with ALS will take a daily nutritional supplement for 8 months. After documenting the ALS symptom history at baseline, the disease severity, and the motor muscles functions will be assessed ...

see more →

News  399 results

Hope, help, and humor when facing a life-threatening illness
https://www.mdedge.com/psychiatry/article/256621/hope-help-and-humor-when-facing-life-threatening-illness
Sarah D. Sosland, BS, Morton D. Sosland, MD

Aug 1st, 2022 - Editor’s note: Readers’ Forum is a department for correspondence from readers that is not in response to articles published in Current Psychiatry. All submissions to Readers’ Forum undergo peer review and are subject to editing for length and styl.

US FDA Accepts Biogen's ALS Therapy for Review
https://www.medscape.com/viewarticle/977954

Jul 27th, 2022 - (Reuters) -Biogen Inc's treatment for a rare type of amyotrophic lateral sclerosis (ALS) was accepted for review by the U.S. health regulator, weeks after follow-up analyses of data from a failed late-stage study suggested the drug was likely to w...

The Hidden Dangers of Pathologizing Grief
https://www.medscape.com/viewarticle/977681

Jul 21st, 2022 - The Weekend That I graduated from law school, my mother told me that she had amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, a neurological disease for which there is currently no cure. As I recalled in a recent essay, I ...

US FDA to Reconvene Experts' Meeting for Amylyx ALS Drug
https://www.medscape.com/viewarticle/976643

Jul 6th, 2022 - (Reuters) -The U.S. Food and Drug Administration will reconvene a meeting of its outside experts to review Amylyx Pharmaceuticals' application for its amyotrophic lateral sclerosis (ALS) treatment, the company said on Tuesday. A panel of outside a...

FDA Unveils 5-Year Plan for ALS, Other Neurodegenerative Diseases
https://www.medscape.com/viewarticle/976169

Jun 24th, 2022 - The US Food and Drug Administration (FDA) has unveiled a 5-year strategy aimed at improving and extending the lives of people with rare neurodegenerative diseases. The agency's Action Plan for Rare Neurodegenerative Diseases including Amyotrophic ...

see more →

Patient Education  16 results see all →